MACUSTAR Study Validates Novel Endpoints for Age-Related Macular Degeneration Clinical Trials

The MACUSTAR (search)Search term consortium has completed a groundbreaking observational study that establishes new standards for clinical trial endpoints in intermediate age-related macular degeneration (search)Search disease (iAMD (search)Search disease). This comprehensive research effort, spanning up to six years across 20 European centers, represents a significant advancement in AMD (search)Search disease research methodology.

Innovative Study Design and Implementation

The study incorporates both cross-sectional and longitudinal components, focusing on developing and validating clinical trial endpoints across multiple assessment domains. Participants aged 55-85 years were evaluated using state-of-the-art imaging technologies, functional assessments, and patient-reported outcomes (PROs).

The research team implemented rigorous quality control measures, including standardized testing protocols and certification requirements for technical staff. Over 128 technicians were certified for imaging procedures, with 93 qualified for visual function assessments, ensuring data consistency across all study sites.

Breakthrough Findings in Visual Function Assessment

Key findings reveal that chart-based and device-based visual function tests achieved high repeatability in multi-center settings. Tests including best-corrected visual acuity, low-luminance visual acuity, and contrast sensitivity demonstrated intra-class correlation coefficients of ≥0.7 in iAMD (search)Search disease patients.

Notably, 71% of iAMD (search)Search disease patients showed impaired performance in at least one visual function parameter compared to healthy controls, highlighting the prevalence of visual deficits in early disease stages.

Advanced Imaging and Structural Assessments

The study utilized a comprehensive multimodal imaging approach, including:

• Spectral-domain and swept-source optical coherence tomography (OCT)
• OCT angiography
• Fundus autofluorescence
• Multi-wavelength confocal scanning laser ophthalmoscopy

These imaging protocols, managed through a central reading center, enabled precise diagnosis and biomarker categorization.

Patient-Reported Outcomes Innovation

A significant advancement emerged with the validation of the Vision Impairment in Low Luminance (VILL) questionnaire, specifically designed for early AMD (search)Search disease stages. The questionnaire demonstrated:

• High repeatability with intra-class correlations ≥0.7
• Significant prognostic value for progression from iAMD to late AMD
• Successful cross-cultural adaptation across multiple European languages

Clinical Trial Implications

The study's findings provide crucial insights for future iAMD (search)Search disease clinical trials:

• Validated functional endpoints beyond traditional anatomical markers
• Established reliability of multi-center visual function testing
• Confirmed prognostic value of both structural and functional biomarkers
• Demonstrated feasibility of complex visual function assessments in multi-center settings

Biomarker Development and Future Directions

The research has identified promising biomarkers for disease progression, including reticular pseudodrusen (search)Search term and mesopic microperimetry pattern standard deviation. These findings, combined with ongoing genetic and biobank analyses, are expected to enhance understanding of iAMD (search)Search disease subtypes and progression patterns.

The MACUSTAR (search)Search term study continues to generate insights through international collaborations and biobank analyses, positioning itself as a cornerstone for future AMD (search)Search disease research and therapeutic development.